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Liver disease is a highly prevalent disease that is one of the
leading causes of death worldwide. The continuous exposure
of the liver to some factors such as viruses, alcohol, fat, and
biotransformed metabolites can cause hepatic injury, which
can lead to inflammation and liver degeneration. When the
injury is sustained for long time, it can cause chronic liver
diseases (CLDs), which include a spectrum of disease states
ranging from simple steatosis and steatohepatitis (steatosis
with inflammation and hepatocyte injury and death) to fibro-
sis, cirrhosis, and hepatocellular carcinoma (HCC). Multiple
evidences indicate that oxidative stress and inflammation
are the most important pathogenic events in liver diseases
regardless of etiology. Oxidative stress and inflammation are
not always harmful; they help phagocytes to kill microor-
ganisms and modulate signaling events through redox reg-
ulation. However, unregulated and prolonged imbalance in
the liver between the production of free radicals and/or
reactive oxygen species (ROS) and their elimination by
protective mechanisms (antioxidants) leads to damage of
important biomolecules and cells, with potential impact on
the whole organism causing many chronic diseases. During
liver damage, ROS can induce the generation of proin-
flammatory genes. A critical component of inflammation
is the infiltration of inflammatory cells, like neutrophils,
monocytes, and lymphocytes, to the site of stimulus. At the
site of inflammation, the activated inflammatory cells release
chemical mediators (eicosanoids, cytokines, chemokines,
nitric oxide, etc.) that induce tissue damage and augmented
oxidative stress and reactive species (superoxide, hydrogen
peroxide, hydroxyl radical, etc.). Thus, overexpression of the
proinflammatory genes provokes an intracellular signaling
cascade that produces more ROS, resulting in a vicious
cycle, where increased oxidative stress and inflammatory
lesion promote the pathogenesis of liver diseases. A better
understanding of the basic pathophysiology underlying the
development of steatosis, steatohepatitis, fibrosis, cirrhosis,
and HCC is needed, so that better treatments can evolve for
liver diseases. Thus, this special issue is dedicated to study
the implications of the central roles that oxidative stress and
inflammation play in CLDs, as well as the associated current
and future therapies.
Antioxidant and anti-inflammatory therapy has been
considered to have the possibility of beneficial effects in
the management of liver diseases. In this regard, the group
of S. Li et al. from China (in “Insights into the Role and
Interdependence of Oxidative Stress and Inflammation in
Liver Diseases”) summarize the following: (i) the crucial
roles of oxidative stress and inflammation in the develop-
ment of liver damage and (ii) the relationship and inter-
dependence of these processes and also describe (iii) the
different herbal medicines or derived compounds targeting
oxidative stress and inflammation in various liver diseases.
Also from China, the group of Z. Wang et al. (in “Oxidative
Stress and Liver Cancer: Etiology and Therapeutic Targets”)
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provided a review about the development of liver cancer
from the perspective of cellular and molecular mechanisms
and reported the therapeutic targets of hepatocarcinoma,
suggesting that antioxidants are urgently needed to prevent
carcinogenesis in the liver. On the other hand, U. S. U. Kumar
et al. from Malaysia (in “Redox Control of Antioxidant and
Antihepatotoxic Activities of Cassia surattensis Seed Extract
against Paracetamol Intoxication in Mice: In Vitro and In
Vivo Studies of Herbal Green Antioxidant”) reported the
protective effect of Cassia surattensis seed extract against
paracetamol-induced liver toxicity in mice and described
the antagonist effects of antioxidants during mild colitis.
Moreover, the group of R. Chaphalkar et al. from India
(in “Antioxidants of Phyllanthus emblica L. Bark Extract
Provide Hepatoprotection against Ethanol-Induced Hepatic
Damage: A Comparison with Silymarin”) observed that PEE
possesses potent antioxidant activity against free radicals and
provides significant protection against alcohol-induced liver
damage, thus supporting the therapeutic claims made in
Ayurveda about Phyllanthus emblica for treatment of hepatic
disorders. In recent times, a new puzzle in medical science
has appeared: antioxidants may exert either beneficial or
harmful effects depending on the cellular requirement for
ROS at a particular situation. In this regard, the group of
F. A. Moura et al. from Brazil (in “Colonic and Hepatic
Modulation by Lipoic Acid and/or N-Acetylcysteine Supple-
mentation in Mild Ulcerative Colitis Induced by Dextran
Sodium Sulfate in Rats”) observed that N-acetylcysteine is
a promising antioxidant toward alleviating ulcerative colitis
and hepatotoxicity, but the combination of lipoic acid andN-
acetylcysteine in contrast causes hepatic injury and colonic
inflammation.
Antioxidants and anti-inflammatories also play a crucial
role inmetabolic liver diseases. FromBrazil, A. Paiva et al. (in
“Apolipoprotein CIII Overexpression Induced Hypertriglyc-
eridemia Increases Nonalcoholic Fatty Liver Disease in Asso-
ciation with Inflammation and Cell Death”) demonstrated
that persistent hypertriglyceridemia might be more relevant
to liver inflammation than intracellular lipid accumulation
and that overexpression of apo-CIII increases severity of
diet-induced fatty liver disease. This study will be useful
to develop new targets to treat metabolic liver diseases.
In addition, P. K. Leong and K. M. Ko from China (in
“Schisandrin B: A Double-Edged Sword in Nonalcoholic
Fatty Liver Disease”) suggest that Schisandrin B, a traditional
Chinese herb, may offer potential as a therapeutic agent for
NAFLD, due to its antihyperlipidemic, antioxidant, anti-ER
stress, anti-inflammatory, and anticarcinogenic activities in
cultured hepatocytes in vitro and in rodent livers in vivo.
The reduction of oxidative stress is suggested to be one
of the main mechanisms to explain the benefits of subnor-
mothermic perfusion against ischemic liver damage. In this
regard, T. Carbonell et al. from Spain (in “Subnormothermic
Perfusion in the Isolated Rat Liver Preserves the Antioxidant
Glutathione and Enhances the Function of the Ubiquitin
Proteasome System”) found that subnormothermic perfusion
in the liver can induce oxidative stress concomitantly with
antioxidant glutathione preservation, triggering antioxidant
mechanisms, protecting against ischemic, hypoxic, and toxic
damage. In addition, the group of Y. Zhang et al. from
China (in “Hyperglycemia Aggravates Hepatic Ischemia
Reperfusion Injury by Inducing Chronic Oxidative Stress
and Inflammation”) suggested that chronic oxidative stress,
inflammation, and potential malfunction of antioxidative
system are the reasons why hyperglycemia aggravates hepatic
ischemia reperfusion injury. Biomarkers are necessary for the
evaluation of the severity of oxidative stress in I/R injury;
thus, the group of H. Li et al. form China (in “Renalase as
a Novel Biomarker for Evaluating the Severity of Hepatic
Ischemia-Reperfusion Injury”) demonstrated that renalase,
a ubiquitous flavin adenine dinucleotide-containing amino
oxidase, is a sensitive ROS-responsive gene in hepatocytes
which can serve as an efficient and sensitive biomarker for
the early warning or evaluation of the severity of hepatic I/R
injury.
Liver diseases remain a significant and major health
problem around the world. Current therapies in chronic liver
diseases are limited and liver transplantation is the only
available treatment for end-stage liver disease. This special
issue believes to provide novel, effective, and safe approaches
to create future antioxidant and anti-inflammatory therapies
for patients with CLDs.
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